GLOBALT Investments LLC GA Sells 8,613 Shares of Stryker Corporation $SYK

GLOBALT Investments LLC GA lessened its position in Stryker Corporation (NYSE:SYK) by 47.8% in the 4th quarter, Holdings Channel.com reports. The fund owned 9,397 shares of the medical technology company’s stock after selling 8,613 shares during the period. GLOBALT Investments LLC GA’s holdings in Stryker were worth $3,303,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Czech National Bank grew its stake in shares of Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after buying an additional 3,366 shares during the last quarter. Davis R M Inc. grew its stake in shares of Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after buying an additional 2,512 shares during the last quarter. Terra Alpha Investments LLC purchased a new stake in shares of Stryker in the 3rd quarter worth approximately $1,216,000. Kepler Cheuvreux Suisse SA purchased a new stake in Stryker during the 3rd quarter valued at $27,952,000. Finally, Daymark Wealth Partners LLC boosted its stake in Stryker by 436.0% during the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after purchasing an additional 37,307 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Saturday. Robert W. Baird set a $385.00 target price on Stryker in a report on Friday, May 1st. Leerink Partners initiated coverage on Stryker in a report on Monday, April 13th. They set an “outperform” rating and a $410.00 price target on the stock. Canaccord Genuity Group decreased their price target on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. decreased their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $395.48.

Insider Activity

In other news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.60% of the stock is owned by company insiders.

Stryker Trading Down 0.0%

Shares of SYK stock opened at $306.74 on Monday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The stock’s 50-day moving average price is $329.68 and its 200-day moving average price is $351.50. The stock has a market capitalization of $117.59 billion, a price-to-earnings ratio of 35.50, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.